Best-sell­ing Tagris­so fur­ther out­paces an up­com­ing J&J ri­val, win­ning ap­proval in new NSCLC in­di­ca­tion

As­traZeneca’s flag­ship can­cer drug is adding a new in­di­ca­tion to its fleet.

Fri­day af­ter­noon, the FDA grant­ed Tagris­so the thumbs-up in non-small cell lung can­cer for pa­tients with EGFR mu­ta­tions who had un­der­gone tu­mor re­sec­tion and op­tion­al, stan­dard post­op­er­a­tive ad­ju­vant chemother­a­py. It’s an­oth­er win for the drug as a promi­nent ri­val from J&J con­tin­ues to play catch-up.

The drug, which is on pace to eclipse $4 bil­lion in sales for 2020, had pre­vi­ous­ly been ap­proved in first line metasta­t­ic EGFR-mu­tat­ed NSCLC and sec­ond-line metasta­t­ic NSCLC pa­tients with EGFR T790M mu­ta­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.